Recent Updates
Recently added Catalysts

CHS-0214

Phase 3

Plaque Psoriasis | Small Molecules | Dermatology |Coherus Oncology, Inc.|Trials Updated: Jun 28, 2019

CHS-0214 development status

Highest phase Phase 3
Registered trials 3 across 1 sponsor since Apr 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials3
Total Enrollment1,527

FDA Designations

No designations recorded

CHS-0214 clinical trials

CHS-0214 · 3 trials · 2 indications

Phase 3 3
NCT02486939A Long Term Safety Extension Study (CHS-0214-05)Rheumatoid Arthritis
COMPLETED359 Analytics
NCT02134210Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)Plaque Psoriasis
COMPLETED521 Analytics
NCT02115750Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)Rheumatoid Arthritis
COMPLETED647 Analytics
PHASE3COMPLETED
A Long Term Safety Extension Study (CHS-0214-05)
Rheumatoid ArthritisUnlock trial analytics
PHASE3COMPLETED
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Plaque PsoriasisUnlock trial analytics
PHASE3COMPLETED
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
Rheumatoid ArthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Durability of Response (Maintenance of an ACR20 Response or Greater), Which Was Measured at Each Visit in Subjects of RA
48 Weeks

The ACR20 is a composite endpoint based on the following assessments: 66/68 swollen joint count (SJC) or tender joint count (TJC), Subject's pain assessment (SPA)-visual analog scale (VAS),Subject's global assessment of disease activity (SGA)-VAS,Physician's global assessment of disease activity (PGA)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and High sensitivity C-reactive protein (hs-CRP).The baseline value to assess the ACR20 during this study was the same baseline value used to assess the ACR20 during the parent study (ie, the Week 0 assessment in the parent study). Subjects were considered an ACR20 responder at a visit if compared to baseline in the parent study (CHS-0214-02) they achieved: At least 20% decrease in SJC, At least 20% decrease in TJC, and At least 20% improvement in at least 3 of the following 5 measures: C-reactive protein, HAQ-DI, SPA (using a VAS) for pain,SGA (using a VAS), orPGA (using a VAS).

In Subjects With PsO, Durability of Response (Maintenance of PASI-50 Response or Greater), Which Was Measured at Each Visit.
Week 0,4,12,24,36,48

All PASI score assessors must have demonstrated proficiency at performing the PASI. Every attempt was made to use the same assessor for each subject throughout the study. n subjects with PsO, durability of response (maintenance of a PASI-50 response or greater at each assessment) was based on scoring the PsO lesions on a scale of 0 to 4 for 3 characteristics: erythema, induration, and desquamation, and within 4 anatomical regions: head, trunk, upper extremities, and lower extremities. Within each of these regions, the area of involvement was scored on a scale of 0 to 6, with the total score being a weighted average, and weights defined by the area of involvement. The clinician assessed the subject's PsO lesions according to the PASI and provided this score within the case report form at Weeks 0 (as the Week 48 assessment of the parent study), 4, 12, 24, 36, and 48. Subjects were classified as having a PASI-50 response based upon 50% reduction from baseline of the parent study.

Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12
12-weeks

The Psoriasis Area and Severity Index (PASI) is well established in the medical literature and is internationally the most widely used instrument to assess the severity of Psoriasis. Proportion of subjects achieving PASI-75 from baseline at Week 12. This was the primary endpoint supporting a Biologics Licensing Application in the US.

Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks
12 Weeks

Mean percent changed in PASI from baseline (last non-missing value prior to first dose) at Week 12. This was the primary endpoint supporting the Marketing Authorization Application in the EU.

ACR-20 - 20% Improvement According to American College of Rheumatology Criteria
24-weeks

The primary efficacy endpoint in Part 1 was the percentage of subjects who achieved ACR20 (20% improvement according to American College of Rheumatology criteria) at week 24 compared to baseline (last non-missing value prior to first dose). Subjects were considered an ACR20 responder if when compared to baseline (last non-missing value prior to first dose), they achieved a 20% decrease in SJC (Swollen joint count), 20% decrease in TJC (Tender joint count), and 20% improvement in 3 of the following 5 measures: high sensitivity C reactive protein(hs-CRP), Health Assessment Questionnaire Disability Index(HAQ-DI), subjects global assessment of pain(SPA, VAS), subject's global assessment of disease activity(SGA-VAS), physician's global assessment of disease activity(PGA-VAS)

Secondary Endpoints

Disease Activity Score Using 28 Tender and Swollen Joint Counts, High Sensitivity C-reactive Protein, and Subject's Global Assessment of Disease Activity (DAS28-CRP[4]) <3.2 (ie, Low Disease Activity) at All Visits for All Subjects With RA.
108 Weeks
DAS28-CRP(4) <2.6 (ie, Remission) on All Visits After DAS28-CRP(4) <2.6 Was Achieved for Subjects With RA.
48 Weeks
Mean Percent Change in PASI (Psoriasis Area and Severity Index) From Baseline
Weeks 4, 8, 12, 24, 36, and 48
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CHS-0214EXPERIMENTALCHS-0214 50 mg weekly
Enbrel (etanercept)ACTIVE_COMPARATOREnbrel 50mg twice weekly times 12 weeks

Interventions

NameTypeDescription
CHS-0214DRUGOpen label
EtanerceptDRUGHead-to-head comparison
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Have completed 48 weeks of evaluations in CHS-0214-02 and, at Week 48, had at least an ACR20, or completed 48 weeks of evaluations in CHS-0214-04 and, at Week 48, had at least a PASI-50 Exclusion Criteria: * None

Countries:JapanUnited StatesAustraliaCanadaGermanyIsraelPolandSouth AfricaBelarusFranceHungaryRussiaSpainUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about CHS-0214

What is CHS-0214 used for?

CHS-0214 was developed for the treatment of chronic plaque psoriasis and rheumatoid arthritis. It was studied in adult patients with these inflammatory conditions, including a Phase 3 comparison against Enbrel (etanercept) in plaque psoriasis and a separate Phase 3 comparison in rheumatoid arthritis.

Who is developing CHS-0214?

CHS-0214 was developed by Coherus Oncology, Inc., which trades under the ticker CHRS. The company sponsored the clinical program evaluating CHS-0214 in plaque psoriasis and rheumatoid arthritis, including Phase 3 active-controlled studies and a long-term safety extension study.

What phase is CHS-0214 in?

CHS-0214 reached Phase 3 clinical development. Its Phase 3 program included active-controlled comparisons against Enbrel (etanercept) in plaque psoriasis and rheumatoid arthritis, plus a long-term safety extension study conducted in Japan. All of these trials are listed as completed.

What clinical trials is CHS-0214 in?

CHS-0214 was studied in Phase 3 trials including NCT02134210, which compared CHS-0214 to Enbrel in 521 patients with chronic plaque psoriasis across the United States, Australia, Canada, Germany, Israel, Poland, and South Africa, and NCT02115750, which compared the two treatments in 647 patients with rheumatoid arthritis.

How many patients were enrolled in CHS-0214 trials?

The CHS-0214 clinical program enrolled 1,006 patients in total across its randomized, double-blind, active-controlled studies. The rheumatoid arthritis trial enrolled 647 patients, the plaque psoriasis trial enrolled 521 patients, and the long-term safety extension study in Japan enrolled 359 patients.

Is CHS-0214 the same as etanercept?

CHS-0214 was evaluated as a proposed biosimilar to Enbrel (etanercept). Its Phase 3 trials were designed as direct comparisons of CHS-0214 to Enbrel in patients with chronic plaque psoriasis and rheumatoid arthritis, with the comparator arm receiving etanercept.